A phase 1 trial of PSCA-targeting #CARTcell therapy in patients with #PSCA positive #prostate cancer demonstrates the treatment, using reduced lymphodepletion, is safe and shows preliminary clinical activity. Tanya Dorff Saul “Cancer Asskicker” Priceman. nature.com/articles/s4159…

📺 WATCH: Saul Priceman, PhD, discuss the benefit of using CAR T-cell therapy for patients with metastatic castration-resistant prostate cancer. #pcsm | Saul “Cancer Asskicker” Priceman cancernetwork.com/view/assessing…

After 14 cherished years at City of Hope, I decided to leave for a wonderful opportunity at USC. This was my first week, and I am super proud to be a Trojan! Fight On!

#Cancer cells spread to #CSF by interacting with the choroid plexus, creating a supportive environment. We discovered they raise #GABA levels in choroid plexus through a specific pathway, and blocking this process can improve treatment for #LMD. USC Brain Tumor Center (uscbtc) @NCICancerBio SNO

LIVE at #Tandem25: Saul Priceman, PhD (Saul “Cancer Asskicker” Priceman) of USC presents ‘Advancing Cellular Immunotherapy for Solid Cancers.’ A deep dive into the progress and potential of cellular therapies for solid tumor treatment. #MoffittTandem25

Advancing T cell therapies for solid cancers! Saul Priceman (Saul “Cancer Asskicker” Priceman) from USC discusses cutting-edge developments at #iwCART25. Targeting solid tumors with next-gen T cells! 🧬🎯 #SolidCancers #TcellTherapy

Gregory Chesnut Johns Hopkins Medicine Next up we have Dr. Saul Priceman from USC present his work on Advancing Cellular Immunotherapy for Solid Cancers.

Congratulations to Dr. John Murad, Assistant Professor of Research in the laboratory of Dr. Saul “Cancer Asskicker” Priceman, USC Norris member and Founding Director of KSOM/NCCC Center for Cancer Cellular Immunotherapy Research.  Dr. Murad was awarded the Tower Cancer Research Foundation Career

New! Online now: Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming dlvr.it/TKZGgL

Robust differentiation of NK cells from MSLN.CAR-IL-15-engineered human iPSCs with enhanced antitumor efficacy against solid tumors science.org/doi/10.1126/sc… Science Advances

🧬 Cracking the Solid Tumor Code 🧬 Bispecific T cell engagers (BiTEs) like blinatumomab have revolutionized 🩸 blood cancer treatment — but in 🧱 solid tumors, they’ve faced major roadblocks: ❌ Few safe, targetable antigens ❌ “Cold” tumor microenvironments that hide from

New #JITC article: Universal off-the-shelf combination immunotherapy using oncolytic viruses to redirect T cell engagers to target solid tumors bit.ly/4mG2TUg Saul “Cancer Asskicker” Priceman USC

🔟 𝗧𝗼𝗽 𝟭𝟬 𝗠𝘂𝘀𝘁-𝗥𝗲𝗮𝗱 𝗨𝗽𝗱𝗮𝘁𝗲𝘀 𝗶𝗻 𝗜𝗺𝗺𝘂𝗻𝗼-𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗧𝗵𝗶𝘀 𝗪𝗲𝗲𝗸 This Week’s Spotlight by OncoDaily Immuno-Oncology. From groundbreaking research on FOXP3 isoforms to advancements in tumor-infiltrating lymphocyte (TIL) therapy for melanoma

Our new publication in Casey Hales on engineering CAR T cells with a secreted anti-PDL1-IL12 fusion for the treatment of solid tumors. Congrats to John P. Murad and our collaborators. Thanks to PCF, @DeptofDefense, and foundations! USC Norris Comprehensive Cancer Center City of Hope nature.com/articles/s4155…